SLC16A1 and hematopoietic and lymphoid cell neoplasm: Analysis of SLC16A1/SLC16A3 expression ratio in 205 hematological cancer cell lines, identified 44 cell lines, primarily of lymphoid origin, that are predicted to be sensitive to AZD3965.